Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Cancer
- Non -Small Cell Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cancer
- Transitional Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: Dose escalation scheme; Single patient cohorts on the first three dose levels, 3+3 afterwards.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03927573
- Collaborators
- GCP-Service International Ltd. & Co. KG
- Investigators
- Principal Investigator: Ralf Bargou, Prof. Dr. Universitätsklinikum Würzburg, CCC Mainfranken
Get Well Soon